Education
About Us
Working with TipRanks
Follow Us
AlphaTON Capital (ATON)
NASDAQ:ATON
ATON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.95 - $23.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)75.24K
Market Cap
$13.42M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,278,622
10 Day Avg. Volume125,413
30 Day Avg. Volume75,240
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ATON FAQ
What was AlphaTON Capital’s price range in the past 12 months?
AlphaTON Capital lowest stock price was $2.95 and its highest was $23.01 in the past 12 months.
What is AlphaTON Capital’s market cap?
AlphaTON Capital’s market cap is $13.42M.
When is AlphaTON Capital’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AlphaTON Capital’s earnings last quarter?
Currently, no data Available
Is AlphaTON Capital overvalued?
According to Wall Street analysts AlphaTON Capital’s price is currently Overvalued.
Does AlphaTON Capital pay dividends?
AlphaTON Capital does not currently pay dividends.
What is AlphaTON Capital’s EPS estimate?
AlphaTON Capital’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlphaTON Capital have?
AlphaTON Capital has 2,278,622 shares outstanding.
What happened to AlphaTON Capital’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AlphaTON Capital?
Currently, no hedge funds are holding shares in ATON
Company Description
AlphaTON Capital
Portage Biotech Inc. (PRTG) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company operates primarily in the health care sector, specifically targeting the treatment of cancer through its proprietary platform technologies and a robust pipeline of novel therapeutics. Portage Biotech aims to enhance the body's immune response to fight cancer, offering potential breakthroughs in cancer treatment.
AlphaTON Capital (ATON) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Can-Fite BioPharma
―
Phio Pharmaceuticals
―
Cellectar Biosciences
―
MetaVia
―
Bolt Biotherapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.85% Other Institutional Investors
99.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---